Non-functioning pituitary microadenoma in children and adolescents: Is follow-up with diagnostic imaging necessary?

Camilla Borghammar1, Ashkan Tamaddon2, Eva-Marie Erfurth3

  • 1Skåne University Hospital, Department of Clinical Sciences, Pediatrics, Pediatric Endocrinology, Lund University, Lund, Sweden. camilla.borghammar@med.lu.se.

Endocrine
|October 17, 2022
PubMed

Insights

Pediatric pituitary microadenomas without hormonal issues show minimal growth. New guidelines suggest tailored follow-up imaging based on lesion size to avoid unnecessary magnetic resonance imaging (MRI) scans.

Area of Science:

  • Pediatric Endocrinology
  • Neuroradiology
  • Oncology

Background:

  • No established follow-up guidelines exist for pediatric pituitary microadenomas.
  • Accurate assessment of lesion growth potential is crucial for appropriate management.

Purpose of the Study:

  • To investigate the growth potential of pituitary solid and cystic lesions under 10 mm in children.
  • To evaluate the accuracy of magnetic resonance imaging (MRI) measurements for these lesions.

Main Methods:

  • Retrospective analysis of 74 children (<18 years) with non-functioning pituitary microadenomas or cysts (<10 mm).
  • Re-evaluation of lesion size across all MRI examinations with a median follow-up of 37 months.
  • Assessment of inter-reader agreement for lesion identification and location, and measurement variability.

Main Results:

  • None of the pituitary lesions without hormonal disturbances showed significant growth during follow-up.
  • Radiologists disagreed on lesion identification in 14% and location in 22% of MRI examinations.
  • Size differences >2 mm, considered significant progression, occurred in only 7% of measurements.

Conclusions:

  • Non-functioning pituitary microadenomas in children exhibit minor size variations, often within the limits of MRI spatial resolution.
  • Proposed follow-up recommendations: clinical follow-up for lesions <4 mm; MRI at 2 years for 4-6 mm lesions; MRI at 1 and 3 years for ≥7 mm lesions.
  • Further MRI is recommended only for new clinical symptoms or hormonal disturbances, indicating no progression.
Abstract